vancomycin-intermediate Staphylococcus aureus (VISA)
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Bacteria
antibiotic-resistant bacterium |
| gptkbp:abbreviation |
gptkb:VISA
|
| gptkbp:associatedWith |
hospital-acquired infections
|
| gptkbp:cause |
gptkb:pneumonia
endocarditis bacteremia |
| gptkbp:causedBy |
gptkb:Staphylococcus_aureus
|
| gptkbp:firstReported |
1997
|
| gptkbp:foundIn |
clinical settings
|
| https://www.w3.org/2000/01/rdf-schema#label |
vancomycin-intermediate Staphylococcus aureus (VISA)
|
| gptkbp:mechanismOfResistance |
cell wall thickening
|
| gptkbp:minimumInhibitoryConcentration |
4-8 μg/mL
|
| gptkbp:monitors |
gptkb:World_Health_Organization_(WHO)
gptkb:Centers_for_Disease_Control_and_Prevention_(CDC) |
| gptkbp:notableCase |
Japan, 1997
|
| gptkbp:publicHealthConcern |
yes
|
| gptkbp:relatedTo |
gptkb:methicillin-resistant_Staphylococcus_aureus_(MRSA)
|
| gptkbp:resistanceLevel |
intermediate
|
| gptkbp:resistantTo |
vancomycin
|
| gptkbp:treatmentChallenge |
limited antibiotic options
|
| gptkbp:bfsParent |
gptkb:Vancomycin
|
| gptkbp:bfsLayer |
5
|